Targeting KRAS in Cancer: Promising Therapeutic Strategies

SIMPLE SUMMARY: Since the Kirsten rat sarcoma viral oncogene homolog (KRAS) is mutated in about 25% of all human cancers and is at the center of pathways involved in tumorigenesis, it is necessary to compile and highlight the novel therapeutic strategies behind targeting this oncoprotein in cancer....

Descripción completa

Detalles Bibliográficos
Autores principales: Mustachio, Lisa Maria, Chelariu-Raicu, Anca, Szekvolgyi, Lorant, Roszik, Jason
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7999304/
https://www.ncbi.nlm.nih.gov/pubmed/33801965
http://dx.doi.org/10.3390/cancers13061204

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7999304/
https://www.ncbi.nlm.nih.gov/pubmed/33801965
http://dx.doi.org/10.3390/cancers13061204

Ejemplares similares